Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01232452 · ClinicalTrials.gov registry record · Phase 2
A Study in Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 172
- Enrollment target
NCT01232452 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 172 participants.
The verdict
NCT01232452, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 172 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate the hypothesis that cixutumumab given in combination with cisplatin and pemetrexed is superior to cisplatin and pemetrexed as first-line therapy for patients with advanced nonsquamous non-small cell lung carcinoma (NSCLC).
Interventions
- DRUG Cisplatin
- DRUG Pemetrexed
- DRUG Cixutumumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 172 participants |
| Start Date | 2011-04 |
| Est. Completion | 2016-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01232452
The ClinicalTrials.gov registry entry for NCT01232452 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 172 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cisplatin is the first listed.
NCT01232452 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01232452 about?
NCT01232452 is a clinical study titled "A Study in Non-Small Cell Lung Cancer". The primary purpose of this study is to evaluate the hypothesis that cixutumumab given in combination with cisplatin and pemetrexed is superior to cisplatin and pemetrexed as first-line therapy for patients with advanced nonsquamous non-small cell lung carcinoma (NSCLC).
What is the current status of trial NCT01232452?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 172 participants. The study started on 2011-04. Estimated completion is 2016-06.
What interventions are being tested in trial NCT01232452?
The interventions under investigation include: Cisplatin (DRUG), Pemetrexed (DRUG), Cixutumumab (DRUG).
Who is sponsoring clinical trial NCT01232452?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.